Skip to main content
Clinical Trials/NCT05040750
NCT05040750CompletedNot Applicable

Correlation Between Cardiac Markers and Severity of COVID-19 in Egyptian Population

Ain Shams University1 site in 1 country207 target enrollmentStarted: September 1, 2021Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
207
Locations
1
Primary Endpoint
relation between cardiac markers and mortality rate in critically ill COVID 19 patients

Study Overview

Brief Summary

By July 9, 2020, the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had resulted in over 11.8 million confirmed cases and over 545000 deaths. Patients with a history of cardiovascular disease are especially vulnerable and have a bad prognosis. According to the findings, cardiac injury manifested by cardiac biomarker elevation is detected in a significant number of COVID-19 patients and is linked to poor outcomes and mortality. However, it is unclear how effective cardiac biomarkers are in COVID-19 prognosis and how to use these indicators.

Detailed Description

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to >11.8 million confirmed cases with >545000 deaths worldwide by July 9, 2020 Patients with preexisting cardiovascular conditions are particularly at risk and have poor prognosis data suggest that cardiac injury, manifested by cardiac biomarker elevation, is detected in a sizable of COVID-19 patients and is associated with adverse outcomes and increased mortality. However, how useful cardiac biomarkers are in COVID-19 prognosis and how to utilize these markers have not been well defined The study will include all moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. The primary outcome is the relation between cardiac markers and mortality rate in critically ill COVID 19 patients The secondary outcome is the relationship between cardiac and inflammatory and coagulation markers

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • all moderate to severe COVID 19 patients who were admitted to ICU.
  • Both genders
  • age group 18-60 years

Exclusion Criteria

  • a refusal to participate in the study,
  • pregnant patients,
  • patients aged <18 or >
  • recent history of acute myocardial infarction (< 1 month before admission).

Outcomes

Primary Outcomes

relation between cardiac markers and mortality rate in critically ill COVID 19 patients

Time Frame: 4 month

relate cardiac biomarkers to mortality rate

Secondary Outcomes

  • relation ship between cardiac and inflammatory and coagulation markers(4 month)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Rania Maher Hussien, MD

Assistant professor of Anaesthesia

Ain Shams University

Study Sites (1)

Loading locations...

Similar Trials